Dr. Venugopal, of the Sylvester Comprehensive Cancer Center at the University of Miami, shares her thoughts on results from the phase III COMMANDS trial that were presented at the 2023 American Society of Clinical Oncology Annual Meeting.
Dr. Venugopal, who was not involved in the study, discusses the results and implications of the open-label, randomized trial, which evaluated luspatercept-aamt versus epoetin alfa for the treatment of anemia in adults with very low-, low- or intermediate-risk myelodysplastic syndromes. All patients in the study required red blood cell transfusions and had not previously received an erythropoietin stimulating agent.
Gullimero Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center presented the results of the study during the 2023 American Society of Clinical Oncology Annual Meeting.
Data from the phase III COMMANDS trial will also be presented during the European Hematology Association Congress on June 10.